Background

Antimicrobial resistance (AMR), often described as one of the darkest shadows of modern medicine, is a major threat to global public health. Every year, millions of people die from infections caused by resistant bacteria, but the development of new drugs has not kept pace. This is because bacteria rapidly develop resistance by finding new ways to evade antibiotics. This has led to calls for a shift from a treatment-focused approach to a prevention-focused approach.

Until now, vaccine development has primarily focused on viruses. Bacteria have much larger and more complex genomes than viruses, making it difficult to identify suitable antigens for prevention. Although mRNA vaccine technology has rapidly matured during the COVID-19 pandemic, research on bacterial diseases has been limited. In particular, in developing countries, including the Middle East, it has been virtually impossible to establish an independent next-generation vaccine platform due to technological barriers and infrastructure limitations.

Key Findings

To overcome these limitations, Iranian researchers have identified bacterial-derived immunogenic antigens that can simultaneously induce humoral and cellular adaptive immunity. The researchers designed a vaccine candidate by encapsulating mRNA containing the selected antigen information in lipid nanoparticles (LNPs) to maximize its delivery efficiency into the body. This is the first Iranian study to develop an mRNA vaccine targeting a non-viral microorganism.

In the validation process using animal experiments, the candidate showed promising results. It was confirmed that a large number of antibodies that specifically react to the target bacteria were formed in the vaccinated group. The researchers demonstrated with experimental data that the humoral immune response induced by the vaccine was sufficient to block bacterial infection. This is considered a successful example of applying the advantages of mRNA technology, which has a simpler production process and easier design modifications than conventional protein-based vaccines, to the field of bacteria.

Significance and Prospects

This study has laid the first stepping stone for an mRNA vaccine platform that can prevent non-viral pathogens, especially multidrug-resistant bacteria. If a vaccine for bacterial infections is commercialized, it will be able to fundamentally block the indiscriminate prescription of antibiotics and reduce the incidence of resistant bacteria. The vaccine will serve as a defense line that replaces antibiotics.

However, there are still challenges to be solved before it can be applied clinically. Large-scale clinical trials are needed to confirm whether the immunogenicity observed in animal experiments is also expressed in the same way in humans. Follow-up studies are also essential to optimize antigen design to flexibly respond to various mutations of bacteria. Securing the stability of the LNP platform, such as developing a lyophilized formulation that does not rely on ultra-low temperature distribution networks, is also a practical technical barrier to be solved.